Altimmune, Inc. Reports Q2 2026 Financial Results

What Happened
Altimmune, Inc. announced its financial results for the quarter ended June 30, 2026 and furnished a related press release as Exhibit 99.1 to a Form 8‑K filed on August 12, 2026. The Form 8‑K was signed by Gregory Weaver, Chief Financial Officer.

Key Details

• Item reported: 2.02 — Results of Operations and Financial Condition (press release announcing Q2 2026 results).
• Exhibit furnished: 99.1 — Press Release dated August 12, 2026 (attached to the 8‑K).
• Quarter covered: Three months ended June 30, 2026.
• Form 8‑K filed and signed by CFO Gregory Weaver on August 12, 2026.

Why It Matters
This filing notifies investors that Altimmune has publicly released its quarterly earnings and related financial information; the press release (Exhibit 99.1) contains the specific revenue, expenses, and other metrics investors use to assess performance. Retail investors should review the press release and the company’s full quarterly disclosures for details on revenue, net income/loss, cash position, and any commentary on operations or outlook.